The companies said Thursday that they tested the drug, called sotrovimab, against individual mutations found in the Omicron variant, accordingThe preliminary findings haven’t yet been peer-reviewed, and the drug will need to be tested against the whole spikeGlaxoSmithKline and Vir have previously tested sotrovimab against mutations on other variants, the newspaper reported.
GlaxoSmithKline expects to see results from testing the drug against the full mutated spike protein in the next 2 to 3 weeks, theSotrovimab has been authorized in about a dozen countries, including the U.S., which paid about $1 billion for hundreds of thousands of doses.
Another experimental antibody therapy developed by Adagio Therapeutics appears to work well against the new variant, theAntiviral drugs could also help prevent hospitalization and may be less vulnerable to new variants because they target a different part of the virus, the newspaper reported. Merck and Pfizer have developed antiviral pills, which still require FDA approval.
In addition, Gilead believes its approved IV therapy, called remdesivir, will continue to be effective against the variant, Reuters reported.can have on Omicron and expects to have more information in coming weeks, Reuters reported.
Or maybe it won't do a thing.
Wrong it’s inorganic. The body will flush it out.
Thank God 🙏🏼